Synergic January 2025 Newsletter
Happy New Year from the Synergic Family!
As we welcome 2025, we want to reflect on the strides we've made in the past year and share some exciting milestones ahead.
Celebrating Progress in Parkinson’s Research and Therapy
2024 was a great year for Synergic as we made significant progress in bringing the VT Touch closer to market. With our breakthrough device designation from the FDA, announced in early 2023, we’ve continued to pursue our mission to enhance the quality of life for those living with Parkinson's disease.
Clinical Trials Update
Our pivotal clinical trial is progressing well, and we are still enrolling participants who live in the Portland, Oregon area. Improvements in quality of life and independence observed in our longitudinal trial have shown promising results we expect to see repeated in this study.
Unsuccessful evaluation of curcumin as add-on therapy in patients with Parkinson's disease, 9 months long, low dose 80 mg/day study
Ambroxol update
Hope Biosciences Stem Cell Trial 
